Cargando…
Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
INTRODUCTION: Focal segmental glomerulosclerosis (FSGS) is a rare glomerular disease with high unmet clinical need. Interest in proteinuria as a surrogate end point for regulatory approval of novel treatments has increased. We assessed the relationship between achieving complete remission (CR) of pr...
Autores principales: | Trachtman, Howard, Diva, Ulysses, Murphy, Edward, Wang, Kaijun, Inrig, Jula, Komers, Radko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577371/ https://www.ncbi.nlm.nih.gov/pubmed/37850006 http://dx.doi.org/10.1016/j.ekir.2023.07.022 |
Ejemplares similares
-
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
por: Komers, Radko, et al.
Publicado: (2020) -
Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
por: Komers, Radko, et al.
Publicado: (2017) -
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
por: Barratt, Jonathan, et al.
Publicado: (2023) -
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis
por: Wada, Russell, et al.
Publicado: (2023) -
Molecular Mechanisms of Proteinuria in Focal Segmental Glomerulosclerosis
por: Wen, Yumeng, et al.
Publicado: (2018)